Meloxicam Temporally Inhibits the Expression of Vascular Endothelial Growth Factor Receptor (VEGFR)-1 and VEGFR-2 During Alveolar Bone Repair in Rats

Author(s)

Nunes Arantes, Ricardo Vinicius ^[1] ; Cestari, Tania Mary ^[1] ; Viscelli, Bruno Alvares ^[1] ; Dionisio, Thiago Jose ^[1] ; Garlet, Gustavo Pompermaier ^[1] ; Santos, Carlos Ferreira ^[1] ; de Assis, Gerson Francisco ^[1] ; Taga, Rumio ^[1]

Affiliation

^[1] Univ Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Sao Paulo - Brazil

• Document type: Journal article
• Source: Journal of Periodontology; v. 86, n. 1, p. 162-172, 2015.
• Web of Science Citations: 2

Abstract

Background: Vascular endothelial growth factor (VEGF) plays an important role during angiogenesis and bone repair. This study investigated whether the use of meloxicam alters bone repair via downregulation of VEGF and receptor expression. Methods: One hundred twenty male Wistar rats had their maxillary right incisor extracted. Animals were divided into a control group (CG; n = 60) and a meloxicam-treated group (TG; n = 60) that received either a single daily intraperitoneal injection of 0.9% NaCl or meloxicam 3 mg/kg, respectively, for 7 consecutive days. Alveolar bone repair was evaluated histomorphometrically, whereas VEGF and its receptors were analyzed by immunohistochemistry and quantitative polymerase chain reaction (qPCR). Data were submitted to two-way analysis of variance and Tukey post hoc test with P <0.05. Results: Bone volume density increased significantly (P = 0.001) in both groups with a strong correlation between treatment and periods (P = 0.003). In the TG, a small amount of bone formation occurred compared with the CG between 3 and 21 days. No significant differences in the number of VEGF-positive cells per square millimeter (P = 0.07) and VEGF messenger RNA (mRNA) expression (P = 0.49) were found between groups. Immunostained cells per square millimeter and mRNA expression for VEGF receptor (VEGFR)-1 (P = 0.04 and P <0.001) and VEGFR-2 (P <0.001 for both analysis) showed a strong interaction between treatment groups and periods. In the TG, immunostained cells per square millimeter and mRNA expression for VEGFR-1 were, respectively, 89% and 37% lower from 3 to 10 days compared with the CG, whereas for VEGFR-2, these values were 252% and 60%, respectively, from 3 to 7 days. Conclusion: In rat alveolar bone repair, meloxicam did not affect VEGF expression but downregulated VEGFR expression, which may cause a delay in the bone repair/remodeling process. (AU)

• FAPESP's process: 09/11333-5 - Study of angiogenesis and temporal expression of VEGF and its receptor VEGFR-1/Flt-1 and VEGFR-2/Flk-1 during alveolar bone repair and normal therapeutic use of a non-steroidal anti-inflammatory selective for COX-2 in rats
• Grantee: Ricardo Vinicius Nunes Arantes
• Support Opportunities: Scholarships in Brazil - Master